From the end of August through early September, #CardioTwitter was buzzing with the groundbreaking research presented at the World Cardiology Congress, the largest meeting of heart experts across the globe.
Hosted by the European Society of Cardiology (ESC), the five-day program analyzed clinical trials, explored worldwide discrepancies in heart health, revised practice guidelines for providers specializing in cardiology, and much more.
Below are some of the most talked-about studies, posted on Twitter with the #ESCCongress hashtag.
1. 2019 guidelines for the management of dyslipidaemias
2. 2019 guidelines for diabetes, pre-diabetes and cardiovascular diseases (CVD)
Some of the primary takeaways from the new guidelines include:
- Some sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide receptor agonists (GLP-1RAs) reduce the risk of myocardial infarction, stroke and cardiovascular death in type 2 diabetes patients with high cardiovascular risk.
- Aspirin as primary prevention is no longer recommended for diabetes patients with only moderate cardiovascular risk.
- Lifestyle changes are central to the new guidelines, which emphasize that “even modest weight loss” can slow CVD progression, especially for diabetes patients.
3. New AI can predict heart attacks five years in advance
Using machine learning, researchers at the University of Oxford developed a new biomarker, called the fat radiomic profile (FRP), according to the British Heart Foundation. The FRP can detect “biological red flags” in blood vessels and identify inflammation, scarring and changes to blood vessels, all of which indicate future heart attack risk. Currently, today’s cardiology practices do not use tools that can uncover all possible “red flags” for a future heart attack.
4. 2019 guidelines on chronic coronary syndromes
The main highlights of these guidelines were the revisions to terminology and pretest probability. “Chronic coronary syndromes” (CCS) should replace the term “stable coronary artery disease” because CCS betters captures the dynamic nature of the conditions, especially their instability, experts say. The new model for pretesting prioritizes dyspnoea as a main presenting symptom.
5. The clinical trial PARAGON-HF
The largest randomized trial performed in patients with heart failure with preserved ejection fraction (HFpEF), PARAGON-HF’s results disappointed many cardiologists. The treatment of sacubitril–valsartan, Novartis’ Entresto, reduced heart failure hospitalizations (first and recurrent) and cardiovascular deaths by 13 percent, but the finding just missed statistical significance. (The p value of was 0.059.)
6. Dapagliflozin as treatment for heart failure with reduced ejection fraction (HFrEF)
Previous research has found that SGLT2 inhibitors reduce the risk of diabetes patients developing heart failure, and improvements appear within weeks of starting treatment. The recent ESC study focused on patients with established heart failure, (with or without diabetes). It found that dapagliflozin led to a statistically significant reduction in the risk of worsening heart and/or CV death by 26 percent.
2019 Guidelines on Dyslipidaemias (Management of), European Society of Cardiology.
2019 Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD, European Society of Cardiology.
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC), European Heart Journal.
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction, New England Journal of Medicine.
Dapagliflozin reduces cardiovascular events in HFrEF, not just diabetes, European Society of Cardiology.
Last updated 9/5/2019